Skip to main content
108 search results for:

Skin cancers 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 26-10-2023 | Toxicities | Teaser

    Looking for coverage of ESMO 2023?

    There's a new home for news and congress coverage! Catch up on all the top stories and latest evidence in oncology research with our ESMO congress hub page.  Learn more »

  2. 20-09-2022 | ESMO 2022 | Conference coverage | Article

    ‘Very strong’ response to first-line enfortumab vedotin–pembrolizumab in advanced urothelial cancer

    He highlighted that skin reactions were observed more frequently with EV plus pembrolizumab than with EV alone, with events of grade 3 or worse occurring in 21.1% versus 8.2% of participants.

  3. 21-06-2022 | Basal cell carcinoma | Adis Journal Club | Article
    Oncology and Therapy

    Basal Cell Carcinoma: A Narrative Review on Contemporary Diagnosis and Management

    Desai Abstract Basal cell carcinoma (BCC) is the most common, accounting for 80–90% of skin cancers.

  4. 28-01-2022 | Basal cell carcinoma | Adis Journal Club | Article
    Advances in Therapy

    New Emerging Treatment Options for Advanced Basal Cell Carcinoma and Squamous Cell Carcinoma

    Authors: Alessia Villani, Luca Potestio, Gabriella Fabbrocini & Massimiliano Scalvenzi  Abstract Non-melanoma skin cancers, also known as keratinocyte tumors, have an increasing incidence worldwide, with basal cell carcinoma and squamous cell carcinoma being the most represented ones.

  5. 09-02-2022 | Adverse events | News | Article

    Women have increased adverse event risk during cancer treatment

    The most common cancers included in the studies were gastrointestinal (26.1%), lung (20.5%), and leukemia (12.1%).

  6. 15-10-2021 | Treatment | Adis Journal Club | Article
    Advances in Therapy

    Non-Surgical Treatments for Keratinocyte Carcinomas

    DOI [Teaser] Key Summary Points Most KCs are cured with surgical excision; however, in some cases particular tumor- or patient-related factors make surgery an unsuitable option Epidermally limited skin cancers can be treated with cryotherapy, photodynamic therapy, or topical treatments Nonsurgical treatment options for low-risk invasive skin cancers include superficial radiation, EDC, and intralesional chemotherapies Locally advanced skin cancers can be treated with targeted therapies, immunotherapies, or systemic chemotherapy

  7. 22-04-2021 | Risk factors | News | Article

    Limited evidence to link antihypertensive use to cancer

    For site-specific cancers, there was generally no evidence that antihypertensive drug use increased the risk for breast, colon, lung, prostate, or skin cancer.

  8. 09-04-2021 | Breast cancer | News | Article

    Risk-based approach feasible for mammography triage in resource squeeze

    The investigators found that the 12.0% of mammograms in the very high- and high-risk groups accounted for 55.0% of all the detected cancers, while the 44.2% of mammograms in the very low-risk category accounted for 13.1% of detected cancers.

  9. 14-02-2021 | ASCO GU 2021 | Conference coverage | Article

    Cisplatin-ineligible advanced UC patients may benefit from enfortumab treatment

    Balar video 2 He also reported on some TRAEs of special interest, including skin reactions, peripheral neuropathy, and hyperglycemia, which occurred at a severity of at least grade 3 in 17%, 8%, and 6% of patients, respectively.

  10. 19-02-2021 | ASCO GU 2021 | Conference coverage | Article

    Enfortumab vedotin outplays chemotherapy in pretreated advanced UC

    TRAEs of special interest included skin reactions, peripheral neuropathy, and hyperglycemia, with grade 3 or more severe events reported in 15%, 5%, and 4% of the enfortumab group, respectively.

  11. 16-02-2021 | ASCO GU 2021 | Conference coverage | Article

    LuPSMA ‘promising alternative’ to cabazitaxel in mCRPC

    At the same time as The Lancet publication, Hofman presented the secondary findings at the 2021 Genitourinary Cancers Symposium.

  12. 15-02-2021 | COVID-19 | News | Article

    Radiotherapy activity changed significantly during first COVID-19 peak

    They add: “By contrast, treatments for oesophageal, bladder, and rectal cancers markedly increased.”

  13. 11-09-2020 | Risk factors | News | Article

    Cancer risk factors described for patients with SLE

    Patients who had previously received cyclophosphamide were at a significantly increased risk for non-melanoma skin cancer (HR=15.3), consistent with existing knowledge that “non-melanoma skin cancers may be triggered by immunosuppressive drugs, for example in organ transplant populations.”

  14. 17-09-2020 | Immunotherapy | News | Article

    ICI therapy tied to reduced second primary cancer risk

    Second primary cancers occurred in 3.9% of patients, but the incidence was significantly lower among individuals who had been treated with ICIs than those who had not, at 0.6% versus 4.0%.

  15. 14-10-2019 | Renal cell carcinoma | News | Article

    SORCE rules out adjuvant sorafenib for RCC

    The presenter expressed surprise not at the type of adverse events but at the severity of these events; for instance, grade 3 hand–foot skin reaction occurred in 24% of participants each in the 3- and 1-year sorafenib treatment arms.

  16. 08-07-2020 | Immunotherapy | News | Article

    NCCN issues patient guidelines on immunotherapy side effects

    The guidance, which draws on the corresponding NCCN guidelines for physicians, includes detailed information on the different types of immune-related adverse events (irAEs), such as endocrine, skin, and musculoskeletal irAEs.

  17. 19-06-2020 | FDA | News | Article
    approvalsWatch

    Pembrolizumab approved for advanced TMB-H solid tumors

    However, the prescribing information  has a “Limitation of Use” reminding physicians that “the safety and effectiveness of pembrolizumab in pediatric patients with TMB-H central nervous system cancers have not been established.”

  18. 09-06-2020 | ASCO 2020 | News | Article

    KEYNOTE-426 update ‘continues to support’ pembrolizumab plus axitinib

    Discussing the adverse events of special interest, the presenter said the overall rate of grade 3–5 events in the combination arm was “around 15%”, most commonly hepatitis, colitis, and severe skin reactions.

  19. 13-08-2018 | FDA | News | Article
    approvalsWatch

    Mogamulizumab-kpkc approved for rare NHL subtypes

    The agent carries serious warnings for skin toxicity, infection, autoimmune reactions and complications related to later use of allogeneic stem cell transplantation.

  20. 18-12-2019 | Urothelial cancer | News | Article

    Genetic risk factors identified for urothelial cancers

    “Identification of germline mutations in these patients may allow for enhanced screening and early detection of hereditary cancers in those families for whom testing would not have been undertaken,” they say.

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.